BRCA1/BRCA2 Genetic Testing: Nursing Guide

What is BRCA1/BRCA2 Genetic Testing?

BRCA1/BRCA2 Genetic Testing is germline DNA testing that looks for disease-causing (pathogenic) or likely pathogenic variants in the BRCA1 and BRCA2 genes. These genes normally help repair damaged DNA; when a harmful variant is inherited, lifetime risks for breast, ovarian, pancreatic, prostate, and other cancers are increased compared with the general population, though not everyone with a variant develops cancer.

Overview

Nurses encounter BRCA testing in oncology clinics, breast centers, gynecology, primary-care referral pathways, and high-risk screening programs when personal or breast cancer or ovarian cancer family history suggests hereditary breast and ovarian cancer (HBOC) syndrome. public health guidance and USPSTF emphasize identifying patients who meet criteria for genetic counseling before testing.

standard clinical references Genetics and NCI explain that a positive result means a harmful variant was found; a negative result lowers the chance of a BRCA-related syndrome but does not eliminate all hereditary cancer risk because other genes may be involved. GeneReviews notes that variants of uncertain significance (VUS) should not be used alone to guide major surgical or surveillance decisions — specialist interpretation is required.

Clinical Nursing Focus

Before testing, confirm that genetic counseling (in person or telehealth per policy) and informed consent are documented. After results return, nurses reinforce that management plans (enhanced screening, risk-reducing surgery, chemoprevention) are made with genetics and oncology teams — not at the bedside from a report alone. Escalate acute symptoms (new breast lump, abdominal mass, neurologic changes) according to facility policy regardless of pending genetics.

Genetic Counseling, Consent, and Result Communication Safety

BRCA results change surveillance and family risk conversations for years. Treating a pathogenic variant as an immediate cancer diagnosis — or dismissing a VUS as harmless — can cause overtreatment, missed screening, or preventable distress. Nurses protect patients by guarding consent, privacy, and accurate pre-disclosure teaching.

Highest-risk scenarios

Pathogenic BRCA result communicated without genetics/oncology follow-up scheduled
Patient told to pursue risk-reducing surgery based only on a VUS report
New breast mass or persistent bloating deferred because DNA testing is pending
Cascade testing ordered for relatives without counseling or the known familial variant

Document: counseling and consent, pedigree summary, specimen details, result classification, notifications, disclosure plan, psychosocial support, and urgent symptom escalation.

What BRCA1/BRCA2 Testing Can and Cannot Tell You

This test can help identify:

Pathogenic or likely pathogenic germline BRCA1/BRCA2 variants when counseling criteria are met
Relatives at risk when cascade testing for a known familial variant is offered per CDC guidance
Need for enhanced breast/ovarian surveillance or risk-reducing options discussed with specialists
Information that may influence treatment planning when testing is ordered for personal cancer history

This test cannot:

Diagnose breast, ovarian, or other cancer by itself — clinical evaluation still required
Rule out all hereditary cancer when negative — other genes may be involved per NCI
Guide major surgery from a VUS alone per GeneReviews and laboratory standards
Replace certified genetic counseling, informed consent, and pedigree-based risk assessment

Pre-test Checks for BRCA Counseling and Consent

Verify

✓Correct patient, germline BRCA order, and counseling/consent documented

✓Family history captured (cancer types, ages, lineage)

✓Specimen type matches order (blood vs saliva kit)

✓Privacy and interpreter needs addressed for sensitive results

✓Patient understands results require genetics interpretation

✓Follow-up disclosure appointment planned when results pending

Clarify before proceeding when:

Consent missing or patient cannot explain test purpose after counseling
Order is tumor (somatic) testing but counseling goal is hereditary risk
Known familial variant exists but a generic panel without that variant is ordered
Patient is acutely distressed or coerced by family to test
Saliva kit instructions not reviewed (eating, rinsing, labeling)
Duplicate BRCA testing recently resulted without clinical indication
Team plans to defer evaluation of new breast or abdominal symptoms until DNA returns

Pathogenic, Negative, and VUS BRCA Results in Context

Integrate BRCA classification with personal history, examination, imaging, and family pedigree. Pathogenic results warrant genetics-led management planning; VUS results require caution and reclassification tracking; negative results still need context when strong family history persists.

Clinical context	Pair with BRCA result	Nursing focus
Pathogenic variant, no cancer symptoms	Positive germline BRCA	Support disclosure visit; accurate risk language; cascade teaching per public health guidance
VUS reported	Uncertain variant	Do not alarm; ensure genetics explains limitations and follow-up plan
Negative BRCA with known familial mutation	Negative panel	Notify genetics — targeted familial testing may be required
New breast lump during testing wait	Any BRCA status	Urgent breast evaluation per protocol — do not wait for DNA

On a small screen, swipe or scroll sideways to see the full table.

Screening and Panels That Pair With BRCA Testing

Related test	Why it may be ordered
Breast MRI and mammography	Enhanced screening for many BRCA carriers per public health guidance/NCCN-based pathways
Multigene hereditary cancer panel	When BRCA negative but suspicion remains per genetics assessment
Tumor biomarker / pathology review	Guides treatment when patient has active cancer — distinct from germline testing
Pap smear	Cervical screening — does not replace HBOC genetic assessment
Colonoscopy	May be considered in comprehensive genetics-based cancer screening plans
PSA (when clinically appropriate)	Some male carriers have elevated prostate cancer risk Genetics

On a small screen, swipe or scroll sideways to see the full table.

Consent, Privacy, and Cascade Conversations at the Bedside

Bedside point	Nursing note
Risk vs diagnosis	Never chart that genetics alone confirms active cancer
VUS caution	Do not suggest prophylactic surgery based on uncertain variants
Cascade testing	Relatives need counseling — same familial variant when known
Privacy	Discuss who may access results; use private setting for teaching
Kit errors	Saliva contamination and mislabeling are common pre-analytic risks
Symptoms first	Palpable mass or red-flag symptoms trump pending DNA timelines

On a small screen, swipe or scroll sideways to see the full table.

The clarify / hold rule

Clarify before proceeding when:

Counseling or consent documentation is incomplete
Wrong test type (germline vs somatic) for the clinical question
Familial variant known but not included on requisition
Patient cannot describe basic test purpose at teach-back
Saliva kit instructions were not followed
Positive preliminary result has no disclosure plan
Clinical red flags are being deferred until genetics returns

BRCA Testing in High-Risk Screening Pathways

Diagnostic safety badge: High-risk diagnostic communication — extra safety checks required for consent, privacy, and result disclosure.

Check-before-test protocol

Counseling + consent + pedigree documentation
Correct specimen kit or blood tubes
Labeling and transport per laboratory
Disclosure appointment scheduled
Teach-back on risk vs diagnosis language

Critical teach-back questions

“Can you tell me why BRCA testing is being done for you?”
“What is the difference between a gene result and having cancer today?”
“Who will explain your final results and help your family if testing is positive?”

Care coordination: genetics counselor, oncology, breast center, gynecology, laboratory, social work/behavioral health, and rapid response per institutional protocol for acute symptoms.

BRCA Genetic Testing Quick Safety Checklist

Was counseling and consent completed before the specimen was collected?
Did I teach risk vs diagnosis without guaranteeing outcomes?
Are new cancer symptoms addressed urgently regardless of pending DNA?
Is a genetics disclosure visit scheduled for preliminary positive results?
Did I document cascade testing teaching without pressuring relatives?

Why BRCA1/BRCA2 Genetic Testing is Ordered

BRCA1/BRCA2 testing is ordered when personal or family history suggests inherited cancer risk that meets guideline-based criteria for genetic evaluation.

Clinical Indication	What the Test Answers	Nursing Rationale
Personal history of breast cancer at young age or triple-negative breast cancer	Does tumor profile or age suggest hereditary syndrome?	NCI PDQ and public health guidance note early-onset and certain tumor types increase likelihood of germline BRCA variants; testing supports treatment and family risk assessment.
Strong family history of breast, ovarian, pancreatic, or male breast cancer	Does pedigree meet institutional or USPSTF/NCCN referral thresholds?	public health guidance Bring Your Brave resources highlight family-history assessment as the first step to identify candidates for counseling and testing.
Known BRCA1/BRCA2 variant in a blood relative	Should targeted testing for the familial variant be offered?	public health guidance advises relatives be tested for the same familial mutation when they choose testing — not an unrelated gene panel first.
Ashkenazi Jewish ancestry with relevant cancer history (when policy applies)	Are founder-mutation screening pathways indicated per local protocol?	Some populations have higher carrier rates for specific BRCA variants; laboratories may use targeted panels — follow institutional genetics criteria.

↔ On a small screen, swipe or scroll sideways to see the full table.

Contraindications and Precautions

There are no absolute medical contraindications to DNA collection itself. Testing may be inappropriate without informed consent, adequate counseling, or when the patient cannot act on results — genetics teams define eligibility.

When genetics results must not delay urgent care

Palpable breast mass, skin changes, or bloody nipple discharge — urgent breast evaluation per protocol; do not wait for BRCA results.
Acute abdominal pain, distension, or symptoms suggesting ovarian torsion or advanced malignancy — escalate per clinical pathway.
Suicidal ideation or severe distress after a positive result — involve mental health and genetics support per facility policy.

Interpretation pitfalls

VUS (variant of uncertain significance) — GeneReviews and laboratory standards recommend not using VUS alone for risk-reducing surgery decisions.
Negative BRCA test when a familial variant is known — ensure the laboratory tests for the specific familial mutation.
Somatic BRCA testing on tumor tissue is different from germline HBOC testing — verify order type matches counseling goals.

Escalate If

New cancer symptoms during testing wait — escalate clinical evaluation independent of genetics.
Pathogenic BRCA result with no documented follow-up appointment — notify genetics/oncology per protocol.
Patient reports coercion or lack of understanding of test implications — pause and involve counselor.

Patient Preparation

Preparation focuses on counseling, consent, pedigree documentation, and correct specimen collection — not fasting for standard germline DNA tests unless the laboratory specifies otherwise.

Pre-test checks

✓Confirm genetic counseling session completed or scheduled per institutional policy.

✓Verify informed consent for germline testing is signed and in the chart.

✓Document three-generation family cancer history when available (types, ages at diagnosis).

✓Explain blood draw or saliva kit steps; clarify testing does not diagnose current cancer by itself.

✓Assess psychosocial support needs and preferred language/interpreter services.

✓For saliva kits: avoid food/drink/rinse restrictions per kit instructions (follow manufacturer/lab).

Medications to Review or Hold

Routine medicines seldom invalidate germline BRCA testing. Document therapies for active malignancy separately because treatment plans may follow somatic and germline pathways. Do not stop prescribed drugs unless the prescriber instructs.

Performance — nursing procedure guide

This page is a Tests & Diagnostics guide for BRCA1/BRCA2 Genetic Testing. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).

How the test is performed

Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:

Venipuncture

Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.

Result follow-up at a glance

Nursing workflow on this page — from order to safe action on results:

1

Confirm indication & correct order

2

Coordinate performance per nursing procedure guide (see above)

3

Document pre-analytic preparation & timing

4

Review result with trend & clinical picture

5

Escalate critical or discordant findings

6

Document communication & patient teaching

Results and Interpretation

Laboratories classify variants using standard terminology (pathogenic, likely pathogenic, VUS, likely benign, benign). Nurses chart the classification reported and ensure genetics or oncology interprets management implications.

Reference Range Disclaimer

Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.

Result	Range / Finding	Clinical Meaning	Nursing Action
Negative / not detected	No pathogenic or likely pathogenic BRCA1/BRCA2 variant detected	No known harmful germline variant identified on the performed assay — does not rule out all hereditary cancer syndromes	Continue population-appropriate screening unless high-risk surveillance remains indicated for strong family history per genetics team
Equivocal / borderline	Variant of uncertain significance (VUS)	Insufficient evidence to classify as harmful or benign — may be reclassified over time	Do not change surgical or surveillance plans based on VUS alone; genetics follow-up per GeneReviews
Positive / elevated	Pathogenic or likely pathogenic BRCA1/BRCA2 variant	Increased hereditary cancer risk — penetrance varies by gene, variant, and family history	Notify genetics/oncology per protocol; support cascade testing discussions with relatives; coordinate enhanced screening or risk-reducing options per specialist plan
Not applicable / below detection limit	Not applicable — BRCA testing is not a numeric low/high assay	Not applicable	Not applicable

↔ On a small screen, swipe or scroll sideways to see the full table.

Clinical Urgency and Escalation

BRCA results are not typically reported as a numeric critical laboratory value. Urgency is clinical: new cancer symptoms, mental health crisis, or failure to reach patients with positive results.

Critical Finding	Threshold / Value	Immediate Action
Suspected new malignancy while awaiting genetics	New mass, bleeding, persistent bloating, weight loss, or neurologic deficit	Escalate according to facility policy for diagnostic workup — do not defer imaging or exam until BRCA returns
Positive pathogenic result without follow-up	Pathogenic BRCA1/BRCA2 reported; patient unaware or no appointment scheduled	Notify genetics counselor/oncology; arrange timely disclosure and management planning per protocol
Acute psychological distress after disclosure	Suicidal thoughts, panic, or inability to participate in teaching	Activate behavioral health and genetics support per institutional protocol

↔ On a small screen, swipe or scroll sideways to see the full table.

Stop and Escalate

Escalate according to facility policy when the patient develops new cancer symptoms, mental health crisis, or when a pathogenic result has not been communicated within the time frame defined by your genetics service.

Factors Affecting Results

Germline BRCA testing has important limitations. Nurses prevent harm by avoiding oversimplified bedside interpretation and routing complex questions to genetics professionals.

False Positives

Not applicable in the serology sense — false positives are rare with validated sequencing; mislabeling or sample mix-up is the greater laboratory risk
Misclassification of variants — laboratories may upgrade/downgrade VUS over time
Assuming a negative test rules out all familial risk when another relative carries an untested gene

False Negatives

Technical limitations — large rearrangements or specific variants may require additional methods not performed on every panel
Testing the wrong family variant when a known familial mutation exists
Somatic mosaicism or non-blood sources — rare; genetics selects appropriate specimen

Interfering Factors

Saliva kit contamination or insufficient DNA — follow kit instructions
Recent blood transfusion or allogeneic bone marrow transplant — may affect blood DNA
Incomplete family history leading to wrong test type ordered

Test Limitations

BRCA1/BRCA2 testing does not detect all hereditary cancer genes. Negative results do not eliminate cancer risk. VUS results require specialist follow-up and may change with reclassification. Management should follow genetics/oncology guidelines (e.g., NCCN) — not nursing interpretation alone.

Nursing Responsibilities

Nursing care centers on counseling coordination, consent integrity, specimen accuracy, balanced result communication, psychosocial support, and cascade screening logistics.

Before the Test

✓Verify counseling, consent, and correct test (germline vs tumor testing).

✓Collect/update family history and identify at-risk relatives per pedigree tool.

✓Prepare patient for saliva or blood collection per laboratory kit.

✓Assess literacy, language, and support persons for result disclosure.

During the Test

✓Maintain privacy during sensitive discussions; use interpreter when needed.

✓Label specimens at bedside; confirm two identifiers on tube or kit.

✓Monitor for vasovagal symptoms during phlebotomy when blood is used.

After the Test

✓Track pending results and ensure genetics follow-up is scheduled.

✓Reinforce that relatives may need separate consent for cascade testing.

✓Teach reportable symptoms while awaiting results; document teaching.

✓Document result notification, referrals, and psychosocial resources offered.

Documentation

Documentation should capture counseling, consent, pedigree notes, specimen details, result classification, notifications, and follow-up without implying independent genetic diagnosis.

Example Nursing Note

“Pre-test genetic counseling completed 14:00 with certified counselor (telehealth). Informed consent signed for germline BRCA1/BRCA2 panel. Saliva kit collected per kit instructions; specimen labeled and sent to reference lab. Patient educated that results take several weeks and will be reviewed with genetics. No acute breast symptoms today.”

Key Documentation Points

Counseling date, mode, and counselor credentials when available
Consent status and test name (germline BRCA1/BRCA2)
Family history summary and pedigree tool used if applicable
Specimen type, collection time, and transport
Result classification and genetics/oncology notification
Cascade testing teaching and mental health referrals if needed

Patient and Family Education

Use clear, non-alarmist language aligned with public health guidance and standard clinical references: testing clarifies inherited risk; it does not mean cancer is present now.

✓Explain BRCA testing looks for inherited gene changes that affect cancer risk over a lifetime.

✓Clarify that positive, negative, and uncertain results all need professional interpretation.

✓Describe blood or saliva collection sensations and privacy protections for genetic information.

✓Encourage sharing results with relatives when genetics advises — same familial variant testing.

✓Report new lumps, bloating, bleeding, or persistent pain promptly — do not wait for DNA results.

✓Ask who should attend the results appointment and what questions they want answered beforehand.

📚

BRCA1/BRCA2 Genetic Testing NCLEX practice questions

Practice NCLEX-style clinical judgment focused on BRCA1/BRCA2 Genetic Testing safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.

Select a tab to view orders, results, assessment, and nursing note details for this case.

Order: Germline BRCA1/BRCA2 panel after genetic counseling
Indication: Mother with breast cancer at 46; maternal aunt ovarian cancer at 52
Timing: Saliva kit sent Monday; results expected in 3 weeks
Related orders: Screening mammogram scheduled; no tumor biopsy on this admission

Question 1 — Priority action

After reviewing the case tabs, the nurse notes a preliminary pathogenic BRCA2 variant and the patient believes she already has breast cancer. What is the nurse’s priority action?

Tell the patient mastectomy is required before the genetics appointment Cancel the genetics visit because the lab report is only preliminary Clarify that the variant affects lifetime risk, reinforce pending counselor disclosure, document concerns, and notify genetics per protocol Order STAT mammogram without notifying the primary team

Question 2 — Recognize cues

Which findings from the case tabs should prompt clarification or escalation? Select all that apply

Preliminary pathogenic BRCA2 result awaiting formal disclosure Patient belief that a positive genetic test equals current cancer Scheduled genetics disclosure visit within 24 hours Correctly labeled saliva kit with timely courier pickup Insurance discrimination concern without documented GINA or genetics counseling resources offered

Question 3 — Trend interpretation

Which trends or cues should the nurse treat as concerning while results are finalized?

Trend snapshot
Prior genetic testing none; VUS reclassification hotline not applicable

Select all that apply

New palpable breast lump reported overnight Persistent abdominal bloating and increasing girth over two weeks Stable vitals with counseling visit confirmed for tomorrow Patient asking for written cascade information for siblings Saliva specimen transported same day per protocol

Question 4 — Matrix judgment

Classify each situation for this patient:

Finding	Expected — document and continue monitoring	Requires follow-up — notify team / repeat test	Urgent — immediate escalation
Pathogenic BRCA2 with genetics disclosure visit scheduled within 24 hours
VUS (uncertain significance) on BRCA1 with no pathogenic finding
Negative BRCA panel with strong family history and known familial variant in sister
New hard breast lump with skin dimpling while awaiting final BRCA report

On a small screen, swipe or scroll sideways to see the full table.

Question 5 — Clinical judgment

The patient asks, “Does this gene result mean I already have cancer?” What is the best nursing response?

“Yes — a pathogenic gene always means cancer is present now.” “This result shows a higher lifetime risk; your genetics team will explain screening and options — it is not the same as a cancer diagnosis.” “Ignore the result until your mammogram next year.” “You must tell every relative today before we know the exact variant.”

Question 6 — Documentation (cloze)

Which documentation element is highest priority after a preliminary pathogenic BRCA2 notification?

The highest-priority documentation action is .

Question 7 — Workflow (ordered response)

Before disclosing a preliminary pathogenic BRCA2 result, rank nursing actions (1 = first).

Notify genetics counselor with preliminary report and patient concerns
Confirm disclosure appointment time and private setting for results visit
Provide balanced teaching: gene result reflects risk, not a current cancer diagnosis
Tell the patient to inform all relatives tonight before genetics explains cascade options

Question 8 — Evaluate outcomes

After the disclosure visit, the patient understands surveillance options and denies new breast symptoms. What outcome best shows safe nursing follow-through?

Document disclosure attendance, classification discussed, follow-up imaging referrals placed, and teach-back on reportable symptoms Chart that prophylactic surgery is mandatory within 30 days Cancel all future screening because genetics completed one visit Document only that the patient was anxious without plan or referrals

Answer key & rationale

Next step Timed NCLEX Next Gen–style scenarios on NurseOnShift

Frequently Asked Questions

FAQ

Who should consider BRCA1/BRCA2 genetic testing?

public health guidance and the U.S. Preventive Services Task Force recommend genetic counseling and consideration of BRCA testing for women with specific personal or family patterns of breast, ovarian, tubal, or peritoneal cancer. Eligibility tools use family history — nurses help document pedigrees and referrals but do not replace counselor risk assessment.

Does a pathogenic BRCA result mean the patient already has cancer?

No. In practice, these genes affect DNA repair and cancer risk over time. A pathogenic variant increases lifetime risk; it is not a diagnosis of current malignancy. New symptoms still require prompt clinical evaluation.

What is a variant of uncertain significance (VUS)?

A VUS is a genetic change with unclear clinical impact. GeneReviews and laboratory practice recommend not using VUS alone to guide risk-reducing surgery or intensive surveillance — genetics teams monitor reclassification over time.

Should relatives be tested after a pathogenic BRCA result?

public health guidance advises that family members who choose testing should be tested for the same familial mutation when one is known. Cascade testing helps identify who needs enhanced screening — each relative needs counseling and consent.

Is fasting required before BRCA blood testing?

Usually no special preparation is required for germline DNA blood draws, but saliva kits have specific food, drink, and rinse restrictions — always follow the kit and laboratory instructions.

Can a negative BRCA test rule out all hereditary cancer risk?

No. A negative BRCA1/BRCA2 result lowers the chance of a harmful variant in those genes but does not exclude other hereditary syndromes. Strong family history may still warrant genetics follow-up per NCI and institutional guidelines.

What screening may be discussed after a pathogenic BRCA result?

public health guidance and NCCN-based summaries describe enhanced breast screening (MRI and mammography starting at younger ages for many carriers) and discussion of risk-reducing surgeries or medications — final plans are made by the patient with genetics and oncology specialists.

References

U.S. National Library of Medicine. BRCA1 gene. MedlinePlus Genetics.
https://medlineplus.gov/genetics/gene/brca1/
U.S. National Library of Medicine. BRCA2 gene. MedlinePlus Genetics.
https://medlineplus.gov/genetics/gene/brca2/
National Cancer Institute. Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version. NIH.
https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq
Centers for Disease Control and Prevention. Genetic Counseling for Hereditary Breast and Ovarian Cancer. CDC.
https://www.cdc.gov/breast-ovarian-cancer-hereditary/genetic-counseling/index.html
Petrucelli N; Daly MB; Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. GeneReviews. NIH Bookshelf.
https://www.ncbi.nlm.nih.gov/books/NBK1247/
U.S. Preventive Services Task Force. BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing. Recommendation statement.
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing
Centers for Disease Control and Prevention. Talking to Family About Your BRCA Gene Mutation. CDC.
https://www.cdc.gov/breast-ovarian-cancer-hereditary/conversation-tips/index.html
Centers for Disease Control and Prevention. Assessing Risk in Young Patients. Bring Your Brave. CDC.
https://www.cdc.gov/bring-your-brave/hcp/education/assessing-risk-young-patients.html

Editorial Standards & Medical Review

About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.

Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for BRCA1/BRCA2 Genetic Testing.

Policies: Medical Review Process · Editorial Policy · Correction Policy

BRCA1/BRCA2 Genetic Testing: Nursing Guide

📋 Contents

⚡ Quick Facts

💡 Key Takeaway

What is BRCA1/BRCA2 Genetic Testing?

Overview

Genetic Counseling, Consent, and Result Communication Safety

What BRCA1/BRCA2 Testing Can and Cannot Tell You

This test can help identify:

This test cannot:

Pre-test Checks for BRCA Counseling and Consent

Verify

Clarify before proceeding when:

Pathogenic, Negative, and VUS BRCA Results in Context

Screening and Panels That Pair With BRCA Testing

Consent, Privacy, and Cascade Conversations at the Bedside

The clarify / hold rule

Clarify before proceeding when:

BRCA Testing in High-Risk Screening Pathways

Check-before-test protocol

Critical teach-back questions

BRCA Genetic Testing Quick Safety Checklist

Why BRCA1/BRCA2 Genetic Testing is Ordered

Contraindications and Precautions

Patient Preparation

Performance — nursing procedure guide

Result follow-up at a glance

Results and Interpretation

Clinical Urgency and Escalation

Factors Affecting Results

Nursing Responsibilities

Documentation

Patient and Family Education

BRCA1/BRCA2 Genetic Testing NCLEX practice questions

Answer key & rationale

Frequently Asked Questions

Who should consider BRCA1/BRCA2 genetic testing?

Does a pathogenic BRCA result mean the patient already has cancer?

What is a variant of uncertain significance (VUS)?

Should relatives be tested after a pathogenic BRCA result?

Is fasting required before BRCA blood testing?

Can a negative BRCA test rule out all hereditary cancer risk?

What screening may be discussed after a pathogenic BRCA result?

References

Related Topics

Pancreatic Cancer

Prostate Cancer

Fatigue

Pap Smear

Colonoscopy

Specimen Collection

Editorial Standards & Medical Review

Contents

Quick Facts

Key Takeaway